SAN DIEGO, Sept. 20, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the following healthcare and investor conferences in upcoming weeks:
Noble Financial BioXposition (BIOX), University of Connecticut, Stamford Campus, Stamford, CT, September 24 at 4:00 PM ET
MD Becker Third Annual "Cancer Immunotherapy: A Long Awaited Reality" Conference, New York Academy of Medicine, New York, NY, October 4 at 9:15 AM ET
Investment in Innovation (IN3) Medical Device 360° Summit, Intercontinental Mark Hopkins, San Francisco, CA, October 16 at 10:30 AM PT
In addition, Mr. Dhillon will attend the exclusive Burrill & Company Biotech Meeting in Laguna Beach, CA on October 7-9 and the Cowen Group 15th Annual Therapeutics Conference in New York, NY on October 10.
Following the Noble Financial and MD Becker events, a video webcast of the presentations can be viewed on OncoSec's website at: http://oncosec.com/index.php/press-media/events-media/
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunothera
|SOURCE OncoSec Medical Inc.|
Copyright©2012 PR Newswire.
All rights reserved